Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, ottobre 14
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
INmune Bio Inc
INMB
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.68
-0.10
-5.62%
Ult. Agg.: Oct 14, 7:26 AM
$1.68
-0.10
-5.62%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
INmune Bio Financials
INmune Bio (INMB) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
INmune Bio Q2 EPS $(0.05) Beats $(0.21) Estimate
Benzinga Newsdesk
PRO
INmune Bio Q1 EPS $(0.20) Beats $(0.22) Estimate.
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.22) by 9.09 percent. This is a 53.49 percent increase over losses of $(0.43) per share from the
Benzinga Newsdesk
PRO
INmune Bio Q4 EPS $(0.18) Beats $(0.24) Estimate
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 25.93 percent. This is a 55 percent increase over losses of $(0.40) per share from the same
Benzinga Newsdesk
Earnings Scheduled For March 30, 2026
Benzinga Insights
PRO
INmune Bio Q3 Adj. EPS $(0.24) Beats $(0.33) Estimate
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.33) by 26.15 percent. This is a 60 percent increase over losses of $(0.60) per share from the same
Benzinga Newsdesk
Earnings Scheduled For October 30, 2025
Benzinga Insights
